Rithm Acquisition Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $309.7M
- Price
- $10.53
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.19%
- Volume
- 220
About
Rithm Acquisition Corp. functions as a special purpose acquisition company (SPAC), established with the explicit aim of pursuing and finalizing a business combination. This could encompass a variety of transactions, such as a merger, an exchange of shares, an asset acquisition, a stock purchase, a corporate reorganization, or similar arrangements with one or more existing enterprises. The entity officially commenced operations on November 21, 2024, and its principal offices are situated in New York, New York.
Quick stats
Shares outstanding29.4M
Computed float21.0M
Float / shares71.5%
Key info
SectorFinancial Services
IndustryShell Companies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002047497
AI Summary
AI-generated1/7
standardbullishclinical trial
Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
Racura Oncology announced that the independent Safety Review Committee (SRC) has recommended continuing its ongoing CPACS Phase 1 clinical trial.
The SRC reviewed safety data from Cohort 1, which tested 40mg/m2 of RC220 alone and in combination with 60mg/m2 of doxorubicin, and noted no safety concerns.
Racura will now proceed to screen patients for Cohort 2, which will test a higher dose of 80mg/m2 RC220 using an updated protocol that includes a lead-in safety cycle of doxorubicin.